Skip to main content

Teva R&D Chief Eric Hughes to Leave; David Gardiner Named Transition Lead

Teva announced on November 18 that Dr. Eric Hughes, its executive vice president of global research and development and chief medical officer, has decided to leave after accepting an offer outside the company. Hughes will remain with the Israeli pharmaceutical company over the coming months to help manage the handover. Dr. David Gardiner, who heads innovative medicines and clinical development, takes over immediately as R&D transition lead. He will report directly to president and chief executive Richard Francis until a permanent successor is appointed. Francis credited Hughes with helping reshape the research organization and strengthen its pipeline and capabilities. Francis said, “Our strategy, priorities and expectations have not changed…” Hughes said he was proud of the research organization’s achievements and the team it had assembled, and thanked his colleagues. The company presented its pipeline and research capabilities at its R&D Day the previous week. At that November 11 event, Teva outlined its ambition to reach $6–7 billion in annual innovative-medicines revenue by 2030. It said revenue from those medicines had more than doubled since the launch of its Pivot to Growth strategy in 2023. Teva is beginning a comprehensive search for Hughes’s permanent successor immediately.

Sources

Teva Pharmaceutical Industries Ltd.Source Language: English12
Courtroom-sketch editorial illustration of an archival Teva Canada industrial facility in Markham, Ontario, with parked cars and trees, providing company context

Commentary

Add Your Voice
Loading comments…

Related articles

  1. Lineage Acquires Huntington’s Cell Therapy Program and Plans Manufacturing Transfer
  2. Biolojic Design Announces FDA Clearance for BD200 Cancer Trial
  3. PolyPid Narrows Quarterly Loss to $5.8 Million, Reports $15.5 Million Cash Balance
  4. Teva CEO Says Stronger Cash Flow Allows Larger Business-Development Opportunities
  5. Mordechai Aviv Seeks Shareholder Approval for Chair to Serve as Interim CEO

Voices

Write about thisPost a clip

Something went wrong

We couldn't complete that action. Check your connection and try again.